The Trump administration has been directly engaging with the pharma industry to implement MFN pricing since the announcement in May. Alongside with agreeing to MFN pricing, Pfizer will offer its products on the new federally operated direct-to-consumer (DTC) website, TrumpRx. It is clear that Trump is easing IRP into the US by introducing MFN pricing into Medicaid first. The Trump administration hopes to launch TrumpRx and implement MFN pricing for Medicaid by early 2026. Pfizer CEO Albert Bourla had hailed the deal with the Trump administration and called it a win-win situation for Americans and Pfizer.